Cancer development, progression, metastasis, and chemoresistance are all influenced by the tumor-immune microenvironment. Dynamic interactions between the tumour cells and their microenvironment during tumour growth pave the way for tumour survival, invasion, metastasis, and resistance to anti-cancer therapy. The establishment of cellular programmes in cancer and immune cells is dependent on genomic and epigenomic pathways. Discovery of various non-coding RNAs including long-noncoding RNAs, microRNAs, PIWI-interaacting RNAs opens up a new avenue for investigating the regulation of the tumors immune microenvironment (TIME). Tumor cells and their surrounding microenvironment may undergo certain changes to escape the detection and removal by the immune system. Non-coding RNAs can influence tumour egress from immune monitoring, hence increasing metastasis and drug resistance. Non-coding RNAs can be used as a therapeutic target to improve immunotherapy efficacy, and research to modulate the TIME to minimize metastasis.
The nature of unique cell type-specific gene expression, as well as other functional evidence, supports the idea that lncRNAs and miRNAs serve diverse biological properties in the tumor immune microenvironment (TIME). How do non-coding RNAs modulate tumor immune microenvironment thereby affecting invasion and metastasis to distant organs? The success of immune checkpoint inhibitors has demonstrated the potential for increasing the survival outcome of patients. However, a significant fraction of patients remains unresponsive largely due to the immunosuppressive tumor environment. Do non-coding RNAs control the responsiveness to cancer immunotherapy. Efficient delivery of miRNA mimics and modified nucleotides to immune cells also possess challenges for the success of immunotherapy.
This special issue will address both fundamental research and clinical aspects that may help in our understanding of the tumor immune microenvironment and the function of non-coding RNAs in tumorigenesis.
Recent advances in cancer and immune cell genomics, as well as immune cell engineering, have therapeutic implications and provide an opportunity for discussion of the challenges, perspectives, and unanswered questions covering the emerging role of transcriptional, epigenetic, and metabolic regulation in cancer and immunity. This Special Issue will cover the most recent experimental advancements and technological improvements in tumor-immune microenvironment, gene editing, gene delivery, and therapeutic techniques for researching immune control in immune-mediated disorders such as autoimmunity and cancer. The objective is to cover this wide field with a series of high-quality, multidisciplinary research papers on overlapping topics in transcriptional and Tumor-immune microenvironment regulation. Original research, methods, review papers, and brief reports will all be considered.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Cancer development, progression, metastasis, and chemoresistance are all influenced by the tumor-immune microenvironment. Dynamic interactions between the tumour cells and their microenvironment during tumour growth pave the way for tumour survival, invasion, metastasis, and resistance to anti-cancer therapy. The establishment of cellular programmes in cancer and immune cells is dependent on genomic and epigenomic pathways. Discovery of various non-coding RNAs including long-noncoding RNAs, microRNAs, PIWI-interaacting RNAs opens up a new avenue for investigating the regulation of the tumors immune microenvironment (TIME). Tumor cells and their surrounding microenvironment may undergo certain changes to escape the detection and removal by the immune system. Non-coding RNAs can influence tumour egress from immune monitoring, hence increasing metastasis and drug resistance. Non-coding RNAs can be used as a therapeutic target to improve immunotherapy efficacy, and research to modulate the TIME to minimize metastasis.
The nature of unique cell type-specific gene expression, as well as other functional evidence, supports the idea that lncRNAs and miRNAs serve diverse biological properties in the tumor immune microenvironment (TIME). How do non-coding RNAs modulate tumor immune microenvironment thereby affecting invasion and metastasis to distant organs? The success of immune checkpoint inhibitors has demonstrated the potential for increasing the survival outcome of patients. However, a significant fraction of patients remains unresponsive largely due to the immunosuppressive tumor environment. Do non-coding RNAs control the responsiveness to cancer immunotherapy. Efficient delivery of miRNA mimics and modified nucleotides to immune cells also possess challenges for the success of immunotherapy.
This special issue will address both fundamental research and clinical aspects that may help in our understanding of the tumor immune microenvironment and the function of non-coding RNAs in tumorigenesis.
Recent advances in cancer and immune cell genomics, as well as immune cell engineering, have therapeutic implications and provide an opportunity for discussion of the challenges, perspectives, and unanswered questions covering the emerging role of transcriptional, epigenetic, and metabolic regulation in cancer and immunity. This Special Issue will cover the most recent experimental advancements and technological improvements in tumor-immune microenvironment, gene editing, gene delivery, and therapeutic techniques for researching immune control in immune-mediated disorders such as autoimmunity and cancer. The objective is to cover this wide field with a series of high-quality, multidisciplinary research papers on overlapping topics in transcriptional and Tumor-immune microenvironment regulation. Original research, methods, review papers, and brief reports will all be considered.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
